WebJul 3, 2015 · The objective of this study was to determine the efficacy of a novel, highly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking cell phenotypes important … WebMar 9, 2024 · 卡马替尼 (inc280) 是一种在生化和细胞测定中的高效选择性 met 抑制剂,在耐受良好的剂量下会导致动物中 met 依赖性肿瘤模型的消退。此外,met扩增的实验性 hcc 肿瘤已被证明对卡马替尼高度敏感。在对晚期实体瘤患者进行的 i 期临床研究中,确定了 600
INC280, an orally available small molecule inhibitor of c-MET ... - PubMed
WebJun 10, 2016 · The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent or in combination with INC280 administered orally in adult patients with advanced hepatocellular carcinoma (HCC). WebFeb 9, 2024 · 长春inc280片ii期临床试验-在egfr突变和cmet扩增的晚期非小细胞肺癌中进行的inc280研究 长春无开展的INC280片II期临床试验信息,需要患者受试者,主要适应症为非小细胞肺癌 simply arthur il
Capmatinib (INC280) in METΔex14-mutated advanced non-small …
http://www.changbaicao.cn/trialsdetail-id-12013.html WebJun 11, 2015 · The purpose of this study was to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study, and to assess the anti-tumor activity and safety of INC280 alone, and in combination with erlotinib, versus platinum with pemetrexed in the Phase II of this … WebMar 20, 2015 · Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR -mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study. rayon t650led